Literature DB >> 22564258

Serotype dynamics of invasive pneumococcal disease post-PCV7 and pre-PCV13 introduction in North East England.

K E Chapman1, D Wilson2, R Gorton1.   

Abstract

The 7-valent pneumococcal conjugate vaccine (PCV7) has been included in the routine childhood immunization programme in the UK since September 2006. A population-based study of serotypes causing invasive pneumococcal disease (IPD) post-PCV7 in North East England was conducted using data from a regional enhanced IPD surveillance system. Overall, there was a 20% reduction [95% confidence interval (CI) 5-32] from 12·1 cases/100 000 population in 2006/2007 to 9·7 in 2009/2010. There was a fall in IPD caused by PCV7 serotypes in all age groups, with reductions of 90% (95% CI 61-99) in children aged <5 years, 50% (95% CI 4-75) in persons aged 5-64 years and 66% (95% CI 40-82) in adults aged ⩾65 years. There was a non-significant increase in IPD caused by non-PCV7 serotypes in children aged <5 years of 88% (95% CI -10 to 312) and adults aged ⩾65 years of 12% (95% CI -19 to 50), which was largely caused by serotypes 7F, 19A and 22F. Replacement disease appears to have reduced the benefits of PCV7 in North East England.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22564258      PMCID: PMC9152040          DOI: 10.1017/S0950268812000763

Source DB:  PubMed          Journal:  Epidemiol Infect        ISSN: 0950-2688            Impact factor:   4.434


  22 in total

1.  Effect of clonal and serotype-specific properties on the invasive capacity of Streptococcus pneumoniae.

Authors:  A Sandgren; K Sjostrom; B Olsson-Liljequist; B Christensson; A Samuelsson; G Kronvall; B Henriques Normark
Journal:  J Infect Dis       Date:  2004-02-16       Impact factor: 5.226

2.  Use of seven-valent pneumococcal conjugate vaccine (PCV7) in Europe, 2001-2007.

Authors:  H De Carvalho Gomes; M Muscat; D L Monnet; J Giesecke; P L Lopalco
Journal:  Euro Surveill       Date:  2009-03-26

3.  Worldwide progress in introducing pneumococcal conjugate vaccine, 2000-2008.

Authors: 
Journal:  Wkly Epidemiol Rec       Date:  2008-10-24

Review 4.  The volatile nature of pneumococcal serotype epidemiology: potential for misinterpretation.

Authors:  Steve Black
Journal:  Pediatr Infect Dis J       Date:  2010-04       Impact factor: 2.129

5.  Long term trends introduce a potential bias when evaluating the impact of the pneumococcal conjugate vaccination programme in England and Wales.

Authors:  S Flasche; M Slack; E Miller
Journal:  Euro Surveill       Date:  2011-05-19

6.  Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine.

Authors:  Catherine A Lexau; Ruth Lynfield; Richard Danila; Tamara Pilishvili; Richard Facklam; Monica M Farley; Lee H Harrison; William Schaffner; Arthur Reingold; Nancy M Bennett; James Hadler; Paul R Cieslak; Cynthia G Whitney
Journal:  JAMA       Date:  2005-10-26       Impact factor: 56.272

Review 7.  Epidemiological differences among pneumococcal serotypes.

Authors:  William P Hausdorff; Daniel R Feikin; Keith P Klugman
Journal:  Lancet Infect Dis       Date:  2005-02       Impact factor: 25.071

8.  Indirect effect of conjugate vaccine on adult carriage of Streptococcus pneumoniae: an explanation of trends in invasive pneumococcal disease.

Authors:  Laura L Hammitt; Dana L Bruden; Jay C Butler; Henry C Baggett; Debby A Hurlburt; Alisa Reasonover; Thomas W Hennessy
Journal:  J Infect Dis       Date:  2006-04-27       Impact factor: 5.226

9.  Effect of pneumococcal conjugate vaccine on nasopharyngeal colonization among immunized and unimmunized children in a community-randomized trial.

Authors:  Katherine L O'Brien; Eugene V Millar; Elizabeth R Zell; Melinda Bronsdon; Robert Weatherholtz; Raymond Reid; Jocelyn Becenti; Sheri Kvamme; Cynthia G Whitney; Mathuram Santosham
Journal:  J Infect Dis       Date:  2007-09-17       Impact factor: 5.226

10.  Impact of infant pneumococcal vaccination on invasive pneumococcal diseases in France, 2001-2006.

Authors:  A Lepoutre; E Varon; S Georges; L Gutmann; Daniel Lévy-Bruhl
Journal:  Euro Surveill       Date:  2008-08-28
View more
  10 in total

1.  Increased paediatric hospitalizations for empyema in Australia after introduction of the 7-valent pneumococcal conjugate vaccine.

Authors:  Roxanne E Strachan; Thomas L Snelling; Adam Jaffé
Journal:  Bull World Health Organ       Date:  2012-12-11       Impact factor: 9.408

2.  Characteristics of invasive pneumococcal disease in hospitalized children in Austria.

Authors:  Maria Paulke-Korinek; Herwig Kollaritsch; Michael Kundi; Birgit Schmidle-Loss; Ines Zwazl; Brigitte Laaber; Karin Lakovits; Andreas Vecsei; Ursula Wiedermann; Heinz Burgmann
Journal:  Eur J Pediatr       Date:  2013-11-13       Impact factor: 3.183

Review 3.  Application of radiation technology in vaccines development.

Authors:  Ho Seong Seo
Journal:  Clin Exp Vaccine Res       Date:  2015-07-29

Review 4.  A systematic review of the burden of vaccine preventable pneumococcal disease in UK adults.

Authors:  James D Chalmers; James Campling; Alison Dicker; Mark Woodhead; Harish Madhava
Journal:  BMC Pulm Med       Date:  2016-05-11       Impact factor: 3.317

5.  Increased Invasive Pneumococcal Disease, North East England, UK.

Authors:  Catherine Houseman; Gareth J Hughes; Kaye E Chapman; Deborah Wilson; Russell Gorton
Journal:  Emerg Infect Dis       Date:  2017-01       Impact factor: 6.883

6.  Implications of asymptomatic carriers for infectious disease transmission and control.

Authors:  Rebecca H Chisholm; Patricia T Campbell; Yue Wu; Steven Y C Tong; Jodie McVernon; Nicholas Geard
Journal:  R Soc Open Sci       Date:  2018-02-14       Impact factor: 2.963

7.  Pneumococcal Nasopharyngeal Carriage in Young Healthy Children After Pneumococcal Conjugate Vaccine in Turkey.

Authors:  Ahmet Arvas; Haluk Çokuğraş; Emel Gür; Nevriye Gönüllü; Zeynep Taner; Hrisi Bahar Tokman
Journal:  Balkan Med J       Date:  2017-08-04       Impact factor: 2.021

8.  Pneumococcal Conjugate Vaccine impact assessment in Bangladesh.

Authors:  Abdullah H Baqui; Eric D McCollum; Samir K Saha; Arun K Roy; Nabidul H Chowdhury; Meagan Harrison; Abu Abdullah Mohammad Hanif; Nicole Simmons; Arif Mahmud; Nazma Begum; Salahuddin Ahmed; Ahad M Khan; Zabed Bin Ahmed; Maksuda Islam; Dipak Mitra; Abdul Quaiyum; Miguel A Chavez; Farhan Pervaiz; Catherine H Miele; Holly B Schuh; Rasheda Khanam; William Checkley; Lawrence H Moulton; Mathuram Santosham
Journal:  Gates Open Res       Date:  2018-04-26

9.  Decreasing case fatality rate following invasive pneumococcal disease, North East England, 2006-2016.

Authors:  C Houseman; K E Chapman; P Manley; R Gorton; D Wilson; G J Hughes
Journal:  Epidemiol Infect       Date:  2019-01       Impact factor: 2.451

10.  Serotype-specific differences in short- and longer-term mortality following invasive pneumococcal disease.

Authors:  G J Hughes; L B Wright; K E Chapman; D Wilson; R Gorton
Journal:  Epidemiol Infect       Date:  2016-05-19       Impact factor: 2.451

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.